B-Cellular_component	0	8	Membrane	Membrane	NN	B-NP
O	8	9	-	-	HYPH	B-PP
O	9	17	anchored	anchor	VBN	B-NP
O	18	21	Cbl	Cbl	NN	I-NP
O	22	32	suppresses	suppress	VBZ	B-VP
O	33	36	Hck	Hck	NN	B-NP
O	37	44	protein	protein	NN	I-NP
O	44	45	-	-	HYPH	B-NP
O	45	53	tyrosine	tyrosine	NN	I-NP
O	54	60	kinase	kinase	NN	I-NP
O	61	69	mediated	mediated	JJ	I-NP
B-Cell	70	78	cellular	cellular	JJ	I-NP
O	79	93	transformation	transformation	NN	I-NP
O	93	94	.	.	.	O

O	96	99	The	The	DT	B-NP
O	100	109	mammalian	mammalian	JJ	I-NP
O	110	115	proto	proto	AFX	I-NP
O	115	116	-	-	HYPH	I-NP
O	116	124	oncogene	oncogene	NN	I-NP
O	125	128	Cbl	Cbl	NN	I-NP
O	129	132	and	and	CC	O
O	133	136	its	its	PRP$	B-NP
B-Cell	137	145	cellular	cellular	JJ	I-NP
O	146	156	homologues	homologue	NNS	I-NP
O	157	159	in	in	IN	B-PP
O	160	174	Caenorhabditis	Caenorhabditis	NN	B-NP
O	175	182	elegans	elegan	NNS	I-NP
O	183	184	(	(	(	O
O	184	187	Sli	Sli	NNP	B-NP
O	187	188	-	-	HYPH	B-NP
O	188	189	1	1	CD	I-NP
O	189	190	)	)	)	O
O	191	194	and	and	CC	O
O	195	205	Drosophila	Drosophila	NN	B-NP
O	206	207	(	(	(	O
O	207	208	D	D	NN	B-NP
O	208	209	-	-	HYPH	B-NP
O	209	212	Cbl	Cbl	NN	I-NP
O	212	213	)	)	)	O
O	214	217	are	be	VBP	B-VP
O	218	226	negative	negative	JJ	B-NP
O	227	237	regulators	regulator	NNS	I-NP
O	238	240	of	of	IN	B-PP
O	241	245	some	some	DT	B-NP
O	246	252	growth	growth	NN	I-NP
O	253	259	factor	factor	NN	I-NP
O	260	268	receptor	receptor	NN	I-NP
O	269	278	signaling	signaling	NN	I-NP
O	279	287	pathways	pathway	NNS	I-NP
O	287	288	.	.	.	O

O	289	295	Herein	Herein	RB	B-ADVP
O	296	298	we	we	PRP	B-NP
O	299	303	show	show	VBP	B-VP
O	304	308	that	that	IN	B-SBAR
O	309	312	Cbl	Cbl	NN	B-NP
O	313	316	can	can	MD	B-VP
O	317	327	negatively	negatively	RB	I-VP
O	328	336	regulate	regulate	VB	I-VP
O	337	344	another	another	DT	B-NP
O	345	354	signaling	signal	VBG	I-NP
O	355	363	molecule	molecule	NN	I-NP
O	363	364	,	,	,	O
O	365	371	namely	namely	RB	B-NP
O	372	378	theSrc	theSrc	NN	I-NP
O	378	379	-	-	HYPH	I-NP
O	379	385	family	family	NN	I-NP
O	386	392	kinase	kinase	NN	I-NP
O	393	396	Hck	Hck	NN	I-NP
O	397	399	by	by	IN	B-PP
O	400	409	targeting	target	VBG	B-VP
O	410	412	it	it	PRP	B-NP
O	413	416	for	for	IN	B-PP
O	417	428	degradation	degradation	NN	B-NP
O	428	429	.	.	.	O

O	430	433	Hck	Hck	NN	B-NP
O	433	434	-	-	HYPH	O
O	434	442	mediated	mediate	VBN	B-NP
B-Cell	443	451	cellular	cellular	JJ	I-NP
O	452	466	transformation	transformation	NN	I-NP
O	467	469	of	of	IN	B-PP
O	470	476	murine	murine	JJ	B-NP
B-Cell	477	488	fibroblasts	fibroblast	NNS	I-NP
O	489	491	is	be	VBZ	B-VP
O	492	500	reverted	revert	VBN	I-VP
O	501	503	by	by	IN	B-PP
O	504	511	ectopic	ectopic	JJ	B-NP
O	512	522	expression	expression	NN	I-NP
O	523	525	of	of	IN	B-PP
O	526	527	a	a	DT	B-NP
B-Cellular_component	528	536	membrane	membrane	NN	I-NP
O	536	537	-	-	HYPH	O
O	537	545	anchored	anchor	VBN	B-NP
O	546	552	allele	allele	NN	I-NP
O	553	555	of	of	IN	B-PP
O	556	559	Cbl	Cbl	NN	B-NP
O	560	562	as	as	IN	B-SBAR
O	563	571	assessed	assess	VBN	B-VP
O	572	574	by	by	IN	B-PP
O	575	578	the	the	DT	B-NP
B-Cell	579	587	cellular	cellular	JJ	I-NP
O	588	598	morphology	morphology	NN	I-NP
O	598	599	,	,	,	O
O	600	611	suppression	suppression	NN	B-NP
O	612	614	of	of	IN	B-PP
O	615	624	anchorage	anchorage	NN	B-NP
O	625	636	independent	independent	JJ	I-NP
O	637	643	growth	growth	NN	I-NP
O	643	644	,	,	,	O
O	645	648	and	and	CC	O
O	649	651	an	an	DT	B-NP
O	652	659	overall	overall	JJ	I-NP
O	660	669	reduction	reduction	NN	I-NP
O	670	672	in	in	IN	B-PP
O	673	676	the	the	DT	B-NP
O	677	682	total	total	JJ	I-NP
O	683	691	tyrosine	tyrosine	NN	I-NP
O	692	707	phosphorylation	phosphorylation	NN	I-NP
O	708	714	levels	level	NNS	I-NP
O	715	721	within	within	IN	B-PP
O	722	725	the	the	DT	B-NP
B-Cell	726	731	cells	cell	NNS	I-NP
O	731	732	.	.	.	O

O	733	736	The	The	DT	B-NP
O	737	747	expression	expression	NN	I-NP
O	748	750	of	of	IN	B-PP
O	751	754	Cbl	Cbl	NN	B-NP
O	755	757	at	at	IN	B-PP
O	758	761	the	the	DT	B-NP
B-Cellular_component	762	768	plasma	plasma	NN	I-NP
I-Cellular_component	769	777	membrane	membrane	NN	I-NP
O	778	785	targets	target	VBZ	B-VP
O	786	790	both	both	CC	O
O	791	794	Hck	Hck	NN	B-NP
O	795	798	and	and	CC	O
O	799	805	itself	itself	PRP	B-NP
O	806	809	for	for	IN	B-PP
O	810	824	ubiquitination	ubiquitination	NN	B-NP
O	825	828	and	and	CC	I-NP
O	829	840	degradation	degradation	NN	I-NP
O	840	841	,	,	,	O
O	842	851	requiring	require	VBG	B-VP
O	852	854	an	an	DT	B-NP
O	855	861	intact	intact	JJ	I-NP
O	862	866	RING	RING	NN	I-NP
O	867	873	finger	finger	NN	I-NP
O	873	874	.	.	.	O

O	875	890	Pharmacological	Pharmacological	JJ	B-NP
O	891	901	inhibition	inhibition	NN	I-NP
O	902	904	of	of	IN	B-PP
O	905	908	the	the	DT	B-NP
O	909	919	proteasome	proteasome	NN	I-NP
O	920	928	prevents	prevent	VBZ	B-VP
O	929	932	the	the	DT	B-NP
O	933	944	degradation	degradation	NN	I-NP
O	945	947	of	of	IN	B-PP
O	948	951	Hck	Hck	NN	B-NP
O	952	963	correlating	correlate	VBG	B-VP
O	964	968	with	with	IN	B-PP
O	969	971	an	an	DT	B-NP
O	972	980	increase	increase	NN	I-NP
O	981	983	in	in	IN	B-PP
O	984	987	the	the	DT	B-NP
O	988	1003	phosphotyrosine	phosphotyrosine	NN	I-NP
O	1004	1010	levels	level	NNS	I-NP
O	1011	1017	within	within	IN	B-PP
O	1018	1021	the	the	DT	B-NP
B-Cell	1022	1027	cells	cell	NNS	I-NP
O	1027	1028	.	.	.	O

O	1029	1038	Activated	Activate	VBN	B-NP
O	1039	1042	Hck	Hck	NN	I-NP
O	1043	1046	and	and	CC	I-NP
B-Cellular_component	1047	1055	membrane	membrane	NN	I-NP
O	1055	1056	-	-	HYPH	O
O	1056	1064	anchored	anchor	VBN	B-NP
O	1065	1068	Cbl	Cbl	NN	I-NP
O	1069	1072	are	be	VBP	B-VP
O	1073	1080	present	present	JJ	B-ADJP
O	1081	1083	in	in	IN	B-PP
O	1084	1091	similar	similar	JJ	B-NP
B-Cellular_component	1092	1103	subcellular	subcellular	JJ	I-NP
O	1104	1117	localizations	localization	NNS	I-NP
O	1118	1121	and	and	CC	O
O	1122	1124	co	co	AFX	B-NP
O	1124	1125	-	-	HYPH	I-NP
O	1125	1142	immunoprecipitate	immunoprecipitate	NN	B-NP
O	1142	1143	,	,	,	O
O	1144	1154	suggesting	suggest	VBG	B-VP
O	1155	1159	that	that	IN	B-SBAR
O	1160	1165	their	their	PRP$	B-NP
O	1166	1177	interaction	interaction	NN	I-NP
O	1178	1180	is	be	VBZ	B-VP
O	1181	1189	required	require	VBN	I-VP
O	1190	1193	for	for	IN	B-PP
O	1194	1204	subsequent	subsequent	JJ	B-NP
O	1205	1219	ubiquitination	ubiquitination	NN	I-NP
O	1220	1223	and	and	CC	I-NP
O	1224	1235	degradation	degradation	NN	I-NP
O	1235	1236	.	.	.	O

O	1237	1250	Interestingly	Interestingly	RB	B-ADVP
O	1250	1251	,	,	,	O
O	1252	1256	both	both	CC	O
O	1257	1271	constitutively	constitutively	RB	B-NP
O	1272	1278	active	active	JJ	I-NP
O	1279	1282	and	and	CC	I-NP
O	1283	1289	kinase	kinase	NN	I-NP
O	1289	1290	-	-	HYPH	B-NP
O	1290	1298	inactive	inactive	JJ	I-NP
O	1299	1302	Hck	Hck	NN	I-NP
O	1303	1311	interact	interact	VBP	B-VP
O	1312	1316	with	with	IN	B-PP
O	1317	1320	and	and	CC	O
O	1321	1324	are	be	VBP	B-VP
O	1325	1333	targeted	target	VBN	I-VP
O	1334	1337	for	for	IN	B-PP
O	1338	1349	degradation	degradation	NN	B-NP
O	1350	1352	by	by	IN	B-PP
O	1353	1356	Cbl	Cbl	NN	B-NP
O	1356	1357	.	.	.	O

O	1358	1362	This	This	DT	B-NP
O	1363	1367	work	work	NN	I-NP
O	1368	1379	illustrates	illustrate	VBZ	B-VP
O	1380	1389	alternate	alternate	JJ	B-NP
O	1390	1395	means	mean	NNS	I-NP
O	1396	1398	to	to	TO	B-VP
O	1399	1407	regulate	regulate	VB	I-VP
O	1408	1411	Src	Src	NN	B-NP
O	1411	1412	-	-	HYPH	B-NP
O	1412	1418	family	family	NN	I-NP
O	1419	1426	kinases	kinase	NNS	I-NP
O	1426	1427	,	,	,	O
O	1428	1431	and	and	CC	O
O	1432	1440	suggests	suggest	VBZ	B-VP
O	1441	1445	that	that	IN	B-SBAR
O	1446	1449	Cbl	Cbl	NN	B-NP
O	1450	1453	may	may	MD	B-VP
O	1454	1456	be	be	VB	I-VP
O	1457	1461	able	able	JJ	B-ADJP
O	1462	1464	to	to	TO	B-VP
O	1465	1473	suppress	suppress	VB	I-VP
O	1474	1478	many	many	JJ	B-NP
O	1479	1488	signaling	signaling	NN	I-NP
O	1489	1497	pathways	pathway	NNS	I-NP
O	1498	1502	that	that	WDT	B-NP
O	1503	1506	are	be	VBP	B-VP
O	1507	1516	activated	activate	VBN	I-VP
O	1517	1519	in	in	IN	B-PP
O	1520	1527	various	various	JJ	B-NP
O	1528	1541	proliferative	proliferative	JJ	I-NP
O	1542	1551	syndromes	syndrome	NNS	I-NP
O	1552	1561	including	include	VBG	B-PP
B-Cancer	1562	1568	cancer	cancer	NN	B-NP
O	1568	1569	.	.	.	O

